Study of eosinophil cationic protein serum levels in patients with toxocariasis
Eleonara Marinova Kaneva, Rumen Nenkov Harizanov, Iskra Georgieva Rainova, Iskren Tsvetkov Kaftandjiev, Nina Dimitrova Tsvetkova
Abstract
Introduction: Toxocariasis is a zoonotic helminth infection with difficult diagnosis. Determination of specific IgG antibodies alone does not allow to establish the disease stage and to evaluate the treatment efficacy. Therefore it is necessary to identify additional markers that will assist the diagnosis. The purpose of our study was to identify and monitor eosinophil cationic protein (ECP) levels in patients with toxocariasis confirmed by serology and to compare our data with the literature to determine the relevance of this protein as an indicator for recent infection and the effectiveness of the therapy.
Material and methods: ELISA (CUSABIO) commercial kit was used for determination of ECP concentration. Sixty serum samples were studied from individuals previously tested and confirmed for toxocariasis by the presence of specific anti-Toxocara IgG antibodies in ELISA (Toxocara IgG Rbiopharm) and the presence of specific bands in Western blot as confirmatory test (LD BIO). Twenty serum samples from clinically healthy blood donors were used as a control group.
Results: The mean concentration of serum ECP in the patients with toxocariasis was significantly higher than in clinically healthy subjects. Seventy-two percent of patients affected by toxicariasis showed increased serum concentration of ECP. However, no statistically significant differences were observed in terms of age (p = 0.451) and sex (p = 0.682) of the patients or clinical form of the disease. ECP levels among patients with visceral toxocariasis were relatively higher (mean 22.99 ng / ml ± 13.16 SD) in comparison to those with ocular involvement (15.60 ng/ml ± 9.92 SD). Correlation between the presence of peripheral eosinophilia and the concentration of serum ECP was not also established.
Conclusion: Data from our study give us reason to believe that serum levels of ECP could serve as an additional marker indicating recent infection, especially in patients without marked increase in the blood eosinophils.
Keywords
References
1. Rothenberg ME. Eosinophilia. N Engl J Med. 1998;338(22):1592-600. doi: 10.1056/NEJM199805283382206.
2. Venge P. Monitoring the allergic inflammation. Allergy. 2004;59(1):26-32. doi: 10.1046/j.1398-9995.2003.00386.x.
3. Bjork A, Venge P, Peterson CG. Measurements of ECP in serum and the impact of plasma coagulation. Allergy. 2000;55(5):442-8.
4. Tischendorf FW, Brattig NW, Lintzel M, Buttner DW, Burchard GD, Bork K, et al. Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. Trop Med Int Health. 2000;5(12):898-905. doi: 10.1046/j.1365-3156.2000.00649.x.
5. Kouriba B, Traore HA, Dabo A, Sangare L, Guindo H, Keita AS, et al. Urinary disease in 2 Dogon populations with different exposure to Schistosoma haematobium infection: progression of bladder and kidney diseases in children and adults. J Infect Dis. 2005;192(12):2152-9. doi: 10.1086/498214.
6. Gutierrez-Pena EJ, Knab J, Buttner DW. Immunoelectron microscopic evidence for release of eosinophil granule matrix protein onto microfilariae of Onchocerca volvulus in the skin after exposure to amocarzine. Parasitol Res. 1998;84(8):607-15. doi: 10.1007/s004360050459.
7. Wildenburg G, Darge K, Knab J, Tischendorf FW, Bonow I, Buttner DW. Lymph nodes of onchocerciasis patients after treatment with ivermectin: reaction of eosinophil granulocytes and their cationic granule proteins. Trop Med Parasitol. 1994;45(2):87-96.
8. Asuming-Brempong E, Gyan B, Amoah A, van der Puije W, Bimi L, Boakye D, et al. Relationship between eosinophil cationic protein and infection intensity in a schistosomiasis endemic community in Ghana. Res Rep Trop Med. 2015;6:1-10. doi: https://doi.org/10.2147/RRTM.S51713.
9. Molina HA, Kierszenbaum F, Hamann KJ, Gleich GJ. Toxic effects produced or mediated by human eosinophil granule components on Trypanosoma cruzi. Am J Trop Med Hyg. 1988; 38(2):327-34. doi: 10.4269/ajtmh.1988.38.327.
10. Hamann KJ, Gleich GJ, Checkel JL, Loegering DA, McCall JW, Barker RL. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol. 1990;144(8):3166-73.
11. Chen J, Liu Q, Liu GH, Zheng WB, Hong SJ, Sugiyama H, et al. Toxocariasis: a silent threat with a progressive public health impact. Infect Dis Poverty. 2018;13;7(1):59. doi: 10.1186/s40249-018-0437-0.
12. Magnaval JF, Michault A., Calon N., Charlet JP. Epidemiology of human toxocariasis in La Reunion. Trans R Soc Trop Med Hyg. 1994;88(5):531-3. doi: 10.1016/0035-9203(94)90148-1.
13. Magnaval JF, Berry A, Fabre R, Morassin B. Eosinophil cationic proteinç as a possible marker of active human Toxocara infection. Allergy. 2001; 56(11): 1096-9. doi: 10.1034/j.1398-9995.2001.00284.x.
14. Niedworok M, Sordyl B, Borecka A, Gawor J, Malecka-Panas E. Estimation of eosinophilia, immunoglobulin E and eosinophilic cationic protein concentration during the treatment of toxocariasis. Wiad Parazytol. 2008;54(3):225-30.
15. Weller PF. The immunobiology of eosinophils. N Engl J Med. 1991;324(16):1110-8. doi: 10.1056/NEJM199104183241607.
16. Hogan S, Rosenberg H, Moqbel R, Phipps S, Foster P, Lacy P, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008;38(5):709-50. doi: 10.1111/j.1365-2222.2008.02958.x.
17. Venge P. Soluble markers of allergic inflammation. Allergy. 1994;49(1):1- 8. doi: 10.1111/j.1398-9995.1994.tb00765.x.
18. Herrick JA, Nordstrom M, Maloney P, Rodriguez M, Naceanceno K, Gallo G, et al. Parasitic infections represent a significant health threat among recent immigrants in Chicago. Parasitol Res. 2020;119(3):1139-48. doi: 10.1007/s00436-020-06608-4.
19. Fillaux J, Magnaval JF. Laboratory diagnosis of human toxocariasis. Vet Parasitol. 2013;15;193(4):327-36. doi: 10.1016/j.vetpar.2012.12.028.
20. Mosayebi M, Moini L, Hajihossein R, Didehdar M, Eslamirad Z. Detection of Specific Antibody Reactivity to Toxocara Larval Excretorysecretory Antigens in Asthmatic Patients (5-15 Years). Open Microbiol J. 2016;10:162-7. doi: 10.2174/1874285801610010162.
21. Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol. 2004;113:30-7. doi: 10.1016/j.jaci.2003.10.050.
22. Plotz SG, Abeck D, Seitzer U, Hein R, Ring J. UVA1 for hypereosinophilic syndrome. Acta Derm Venereol. 2000;80(3):221. doi: 10.1080/000155500750043087.
23. Pronk-Admiraal CJ, Bartels PC, Mulder K. Eosinophil cationic protein in serum from nonatopic and asymptomatic atopic individuals after standardized blood clotting at 37◦C. Ann Clin Biochem. 1999;36(pt3):353-8. doi: 10.1177/000456329903600308.
24. Tischendorf FW, Brattig NW, Büttner DW, Pieper A, Lintzel M. Serum levels of eosinophil cationic protein, eosinophil-derived neurotoxin and myeloperoxidase in infections with filariae and schistosomes. Acta Trop. 1996;62(3):171-82. doi: 10.1016/s0001-706x(96)00038-1.
25. McGuinness, SL, Leder K. Global Burden of Toxocariasis: A Common Neglected Infection of Poverty. Curr Trop Med Rep. 2014;1:52–61. doi: https://doi.org/10.1007/s40475-013-0012-5.
26. Meeusen EN, Balic A. Do eosinophils have a role in the killing of helminth parasites? Parasitol Today. 2000;16(3):95-101. doi: 10.1016/s0169- 4758(99)01607-5.
Submitted date:
05/04/2020
Reviewed date:
05/27/2020
Accepted date:
05/27/2020
Publication date:
05/27/2020